Novartis shared positive topline results from two Phase III studies evaluating an investigational oral treatment for relapsing multiple sclerosis.
Public source
Publisher name
Public post
Today, we shared positive topline results from our two Phase III studies evaluating an investigational oral treatment for relapsing multiple sclerosis (RMS). Multiple sc…
Company
Novartis
- Industry
- Pharmaceutical Manufacturing
- Location
- Basel, CH
- Company size
- 10,001+ employees
About Novartis
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
See moreLatest activity
Latest activity from Novartis
44 signals
Partnerships
Novartis and The Max Foundation have partnered for 25 years to help ensure cancer care breakthroughs reach more patients around the world.
Research & Knowledge
Novartis published in the journal NEJM the clinical trial JY231 for lentiviral in vivo CD19 CAR T-cell therapy in neurologic autoimmune disorders.
People
Novartis appointed Gloria F. as Director Strategy International, leading strategic initiatives across International markets.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Chicago MS Alliance
Chicago MS Alliance received a positive readout from the phase 3 remibrutinib trial for relapsing multiple sclerosis from Novartis.
Research & Knowledge
Wyss Zurich
Wyss Zurich published new clinical data from the alumni project Cellerys AG showing encouraging safety, tolerability, and providing insights into potential mechanisms of action for a novel therapy in multiple sclerosis.
Research & Knowledge
Novartis España
Novartis España works in neurobiology with a focus on understanding the origin of genetic diseases and exploring new ways to treat them.
Research & Knowledge
UCB
UCB announced that the first disease-modifying therapy for a rare CNS disorder targeting the underlying GFAP accumulation in astrocytes was approved.
Research & Knowledge
AbbVie